-

$undefined

N/A

(N/A)

Unity Biotechnology Inc NASDAQ:UBX UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

Location: 3280 Bayshore Blvd, California, 94005-1028, US | Website: unitybiotechnology.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

28.08M

Cash

29.04M

Avg Qtr Burn

-5.634M

Short % of Float

3.10%

Insider Ownership

1.31%

Institutional Own.

19.61%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic macular edema	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foselutoclax (UBX1325) (Bcl-xL inhibitor) Details Diabetic retinopathy , Diabetic macular edema, Age-related macular degeneration	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.